Inflammaging in melanoma: Precision control for optimizing immune checkpoint inhibition

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Aging is a risk factor for melanoma, associated with chronic inflammation ('inflammaging').
• Inflammaging can lead to immune dysfunction and reduced efficacy of immune checkpoint inhibitors (ICIs).
• Understanding inflammaging's role in melanoma and ICI response is crucial for improving patient outcomes.

Purpose of the Study:

• To review the role of key inflammaging-associated cytokines (IL-6, IL-1, TNF-α) in melanoma progression.
• To discuss their impact on anti-tumor immunity and response to ICIs.
• To explore strategies for modulating inflammaging to enhance ICI therapy.

Main Methods:

• Literature review focusing on inflammaging, cytokines (IL-6, IL-1, TNF-α), melanoma, and ICIs.
• Analysis of preclinical and clinical evidence regarding cytokine roles and targeted therapies.
• Synthesis of findings to propose a model for selective inflammaging modulation.

Main Results:

• IL-6 is a key mediator linking inflammation to immune suppression and ICI toxicity; selective blockade shows promise.
• IL-1 signaling contributes to melanoma inflammation and immune dysregulation, but clinical data is limited.
• TNF-α has context-dependent roles, potentially mediating anti-tumor immunity or ICI resistance.

Conclusions:

• Selective modulation of pathological inflammaging, not broad immunosuppression, may improve ICI therapeutic index.
• Targeting specific cytokine pathways (e.g., IL-6) offers a viable strategy to optimize melanoma immunotherapy.
• This approach is particularly relevant for melanoma patients with inflammaging-associated conditions.